What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
關於奧洛茲美醫療的13位分析師評級報告
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 1 | 0 | 0 |
| 3M Ago | 3 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.69, a high estimate of $71.00, and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 3.52% increase from the previous average price target of $55.73.
Breaking Down Analyst Ratings: A Detailed Examination
A comprehensive examination of...
登入免費觀看全文
登入/註冊